A Data-Driven Analysis of Pediatric Organ Dysfunction Patterns To Discover Sepsis Phenotypes
对儿科器官功能障碍模式进行数据驱动分析以发现脓毒症表型
基本信息
- 批准号:9895827
- 负责人:
- 金额:$ 20.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-09 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdjuvantAdjuvant TherapyAdrenal Cortex HormonesAdultAdvisory CommitteesAffectAgeAlbuminsBiological MarkersCardiovascular systemCessation of lifeCharacteristicsChildChildhoodClinicalClinical DataComputerized Medical RecordConsensusCreatinineCritical IllnessCritically ill childrenDataData AnalysesDependenceElectronic Health RecordFollow-Up StudiesFoundationsFunctional disorderGeneticHeartHematologyHepaticHospital MortalityHourImmune responseIndividualInfectionInfusion proceduresInternationalKidneyLifeLightLogisticsLungMethodsModelingMolecularMultiple Organ FailureNeurologicOrganOrgan failureOutcomePathway interactionsPatientsPatternPediatric Intensive Care UnitsPerformancePharmaceutical PreparationsPhasePhenotypeReproducibilityResearch PersonnelSepsisSeptic ShockSyndromeTechniquesTestingTherapeuticValidationWeightbasebody systemcohortdesigneffective therapyimprovedindividualized medicineloss of functionmortalitynovelpatient subsetspressureprognosticrespiratoryresponsesecondary analysistheories
项目摘要
PROJECT SUMMARY
Sepsis is a common cause of pediatric multiple organ dysfunction syndrome (MODS), which, in turn, is
a final common pathway for death in most critically ill children. Unfortunately, approaching sepsis as a
uniform clinical syndrome has contributed to dozens of failed drug trials and hundreds of single biomarkers
demonstrating poor performance. In light of this, some sepsis researchers have focused their efforts in
discovering sepsis subtypes that represent the specific pathobiological pattern underlying the syndrome in
different subgroups of patients. These subtypes, in theory, are associated with therapy response and outcomes
and could be used to guide individualized therapy. While optimal methods to uncover sepsis subtypes are still
unclear, there are strong advantages to using a phenotype-based approach, where the clinical characteristics of
patients are used as surrogates of the underlying pathobiology. We hypothesize that the clinical characteristics
of children with sepsis can be adequately quantified using calibrated pediatric organ dysfunction scores and
that the early patterns of organ dysfunction can be used to identify novel phenotypes of sepsis with prognostic
and therapeutic relevance. Existing pediatric organ dysfunction scores are weighted in a multivariable model to
predict mortality and are not designed to represent the progressive loss of function of each individual organ
system. In light of this, we recently adapted and validated a pediatric version of the Sequential Organ Failure
Assessment score (pSOFA) which allocates similar weight to each failing organ system. However, the validation
of pSOFA was performed in a single center and no attempts were made to calibrate the organ-specific
subscores to optimize the grading of each organ dysfunction (i.e. respiratory, cardiovascular, hepatic, renal,
neurologic, and hematologic). In this study, we aim to: 1) re-calibrate and validate the pSOFA subscores using a
multi-center observational cohort of critically ill children with confirmed or suspected infection; and (2)
analyze the early patterns of organ dysfunction in critically ill children with sepsis using the pSOFA subscores
in order to identify novel phenotypes of sepsis with prognostic and therapeutic relevance. We will use Subgraph
Augmented Non-Negative Matrix Factorization to model and visualize the patterns of organ dysfunction during
the acute phase of sepsis. These patterns will form the basis for the characterization of novel sepsis phenotypes.
We will then evaluate whether the novel sepsis phenotypes are associated with outcomes in a validation cohort
and independently associated with response to two common adjuvant treatments: corticosteroids and albumin
infusions. The results from this study will be used as the foundation for follow-up studies to characterize the
underlying molecular and cellular perturbations associated with the identified phenotypes.
项目摘要
败血症是小儿多器官功能障碍综合征(mods)的常见原因,而这又是
大多数重症儿童死亡的最终常见途径。不幸的是,接近败血症
统一的临床综合征已导致数十个失败的药物试验和数百个单个生物标志物
表现出差的性能。鉴于此,一些败血症研究人员将精力集中在
发现代表综合征基础的特定病理生物学模式的败血症亚型
不同的患者亚组。从理论上讲,这些亚型与治疗反应和结果有关
可以用来指导个性化治疗。虽然发现败血症亚型的最佳方法仍然是
尚不清楚,使用基于表型的方法具有很强的优势,在此,
患者被用作基础病理生物学的替代物。我们假设临床特征
使用校准的小儿器官功能障碍评分和
器官功能障碍的早期模式可用于识别具有预后的败血症的新表型
和治疗意义。现有的儿科器官功能障碍分数以多变量模型加权到
预测死亡率,并非旨在代表每个器官的功能逐渐丧失
系统。鉴于此,我们最近改编并验证了连续器官衰竭的儿科版本
评估评分(PSOFA),将相似的重量分配给每个故障器官系统。但是,验证
在单个中心进行psofa,没有尝试校准特定器官
测试以优化每个器官功能障碍的分级(即呼吸,心血管,肝,肾脏,
神经系统和血液学)。在这项研究中,我们的目的是:1)使用
多中心的观察群体批评儿童确认或怀疑感染; (2)
使用psofa subscores分析重病患病儿童的器官功能障碍的早期模式
为了鉴定具有预后和治疗相关性的败血症的新表型。我们将使用子图
增强非负矩阵分解,以建模和可视化器官功能障碍的模式
败血症的急性相。这些模式将构成新型败血症表型表征的基础。
然后,我们将评估新型败血症表型是否与验证队列中的结果相关
并且与对两种常见辅助治疗的反应独立相关:皮质类固醇和白蛋白
输注。这项研究的结果将用作后续研究的基础,以表征
与已鉴定的表型相关的基本分子和细胞扰动。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Excessive Oxygen Supplementation in the First Day of Mechanical Ventilation Is Associated With Multiple Organ Dysfunction and Death in Critically Ill Children.
- DOI:10.1097/pcc.0000000000002861
- 发表时间:2022-02-01
- 期刊:
- 影响因子:0
- 作者:Balcarcel DR;Coates BM;Chong G;Sanchez-Pinto LN
- 通讯作者:Sanchez-Pinto LN
Three Data-Driven Phenotypes of Multiple Organ Dysfunction Syndrome Preserved from Early Childhood to Middle Adulthood.
从幼儿期到成年中期保留的三种数据驱动的多器官功能障碍综合征表型。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Ye,Jiancheng;Sanchez-Pinto,LNelson
- 通讯作者:Sanchez-Pinto,LNelson
External validation and biomarker assessment of a high-risk, data-driven pediatric sepsis phenotype characterized by persistent hypoxemia, encephalopathy, and shock.
对以持续低氧血症、脑病和休克为特征的高风险、数据驱动的儿童脓毒症表型进行外部验证和生物标志物评估。
- DOI:10.21203/rs.3.rs-3216613/v1
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Atreya,MihirR;Bennett,TellenD;Geva,Alon;Faustino,EVincentS;Rogerson,ColinM;Lutfi,Riad;Cvijanovich,NatalieZ;Bigham,MichaelT;Nowak,Jeffrey;Schwarz,AdamJ;Baines,Torrey;Haileselassie,Bereketeab;Thomas,NealJ;Luo,Yuan;Sanche
- 通讯作者:Sanche
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lazaro Nelson Sanchez-Pinto其他文献
Lazaro Nelson Sanchez-Pinto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
穿透性靶向胰腺癌内cDC1的纳米佐剂调控溶酶体逃逸促进放疗诱导ICD的机制研究
- 批准号:82303680
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多级改造的工程化外泌体自佐剂疫苗平台实现鼻上皮细胞感染拟态和粘膜递送的研究
- 批准号:32371440
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
展示PD-L1抗体的纳米锰佐剂联合放疗以诱导原位肿瘤疫苗的产生及其机制的探究
- 批准号:32371518
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
应用于冠状病毒广谱疫苗开发的新型全链式免疫增强型佐剂研究
- 批准号:82341036
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
相似海外基金
Integration of Immunologic Phenotyping with Computational Approaches to Predict Clinical Trajectory in Septic Patients
免疫表型分析与计算方法相结合来预测脓毒症患者的临床轨迹
- 批准号:
10708534 - 财政年份:2023
- 资助金额:
$ 20.93万 - 项目类别:
Epitranscriptomic mechanisms of the antidepressant response to ketamine in human neurons
人类神经元抗抑郁反应的表观转录组机制
- 批准号:
10607430 - 财政年份:2023
- 资助金额:
$ 20.93万 - 项目类别:
Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms
靶向 1-磷酸鞘氨醇 (S1P1) 受体治疗芳香酶抑制剂引起的肌肉骨骼症状
- 批准号:
10668781 - 财政年份:2023
- 资助金额:
$ 20.93万 - 项目类别:
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
干细胞移植后复发性 AML 患者使用低甲基化药物桥接治疗后新型 T 细胞疗法的 2 期临床试验
- 批准号:
10761513 - 财政年份:2023
- 资助金额:
$ 20.93万 - 项目类别:
Duke Testing Site for Stroke Preclinical Assessment Network
杜克中风临床前评估网络测试站点
- 批准号:
10591716 - 财政年份:2023
- 资助金额:
$ 20.93万 - 项目类别: